<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00736476</url>
  </required_header>
  <id_info>
    <org_study_id>V99P2</org_study_id>
    <secondary_id>2007-003511-31</secondary_id>
    <nct_id>NCT00736476</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of an H.Pylori Vaccine in H.Pylori-Negative Adults</brief_title>
  <official_title>Phase I/II, Randomized, Observer-blind, Placebo-controlled, Single-Center Study of the Tolerability, Immunogenicity, and Efficacy of an Novartis' Investigational H. Pylori Vaccine in H. Pylori-Negative Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      To study the safety, immunogenicity and efficacy of an investigational H. pylori vaccine,
      compared with placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Efficacy (Defined as Prevention of Infection) of the HP Vaccine Compared to Placebo.</measure>
    <time_frame>12 weeks post HP challenge</time_frame>
    <description>The efficacy of the investigational vaccine to prevent infection following H.pylori challenge in healthy adults was determined in terms of percentage of subjects with positive HP infections in the vaccinated and unvaccinated groups(Placebo).
Infection rates was assessed by invasive Upper Gastrointestinal Endoscopy (UGE)tests that included HP histopathology, HP culture and rapid urease test (RUT), and non-invasive HP tests which included urea breath test (UBT) and fecal antigen test (FAT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Solicited Local* and Systemic Adverse Events Following Vaccination</measure>
    <time_frame>Day 1-7 post vaccination</time_frame>
    <description>To assess the tolerability of an HP vaccine versus placebo in terms of number of subjects reporting solicited local* and systemic adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Time Course of HP Infection Following HP Challenge in Vaccinated and Placebo Groups</measure>
    <time_frame>12 months</time_frame>
    <description>The time course of HP infection following HP challenge in subjects of the HP vaccine and placebo groups, were assessed by non-invasive HP tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Geometric Mean Concentrations After HP Vaccination.</measure>
    <time_frame>upto 1 month after 3rd vaccination</time_frame>
    <description>The geometric mean concentration of IgG antibody responses to each of the HP vaccine antigens (VacA, CagA and NAP)after HP vaccination as compared to placebo are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations Against Vaccine Antigens After HP Challenge.</measure>
    <time_frame>12 months</time_frame>
    <description>The geometric mean concentration of IgG antibody responses to each of the HP vaccine antigens (VacA, CagA and NAP) after HP challenge were compared between vaccinated and placebo groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response on Activated Regulatory T Cell Subset Following HP Vaccination and HP Challenge</measure>
    <time_frame>12 weeks post HP challenge</time_frame>
    <description>The response to 3 doses of HP vaccine and the oral HP challenge was assessed with respect their ability to induce differentiation and changes in the phenotype of a subset of regulatory T-cells CD4+CD25+Foxp3+ that expresses Treg Markers PD-1 and/or HLA-DR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proliferative Response Against the Pooled H. Pylori Vaccine Antigens by Stimulation Index (SI)</measure>
    <time_frame>12 weeks post HP challenge</time_frame>
    <description>The proliferation of H. pylori-specific Peripheral blood mononuclear cells (PBMCs) following HP antigen stimulation was assessed to measure the magnitude of the cell mediated immune response.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H.pylori vaccines</intervention_name>
    <description>1 dose of H.pylori vaccine at 0, 1, and 2 months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo Vaccine</intervention_name>
    <description>Placebo Vaccine at 0, 1, and 2 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adults 18 - 40 years of age in good health

          -  HP uninfected

          -  not pregnant and agree to use birth control throughout the study (females who can
             become pregnant)

        Exclusion Criteria:

          -  remote or current HP infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Otto von Guericke Universität Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2008</study_first_submitted>
  <study_first_submitted_qc>August 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2008</study_first_posted>
  <results_first_submitted>September 30, 2016</results_first_submitted>
  <results_first_submitted_qc>January 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 28, 2017</results_first_posted>
  <last_update_submitted>January 9, 2017</last_update_submitted>
  <last_update_submitted_qc>January 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>helicobacter pylori infection</keyword>
  <keyword>vaccination</keyword>
  <keyword>adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from a single study center in Germany</recruitment_details>
      <pre_assignment_details>All subjects enrolled were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group I (HP Vaccine)</title>
          <description>Subjects received three injections of HP Vaccine at 0, 1, and 2 months, followed by H.pylori challenge(oral administration of infectious HP inoculum)1 month later.</description>
        </group>
        <group group_id="P2">
          <title>Group II (Placebo)</title>
          <description>Subjects received three injections of Placebo at 0, 1, and 2 months,followed by H.pylori challenge (oral administration of infectious HP inoculum)1 month later.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group I (HP Vaccine)</title>
          <description>Subjects received three injections of HP Vaccine at 0, 1, and 2 months.</description>
        </group>
        <group group_id="B2">
          <title>Group II (Placebo)</title>
          <description>Subjects received three injections of Placebo at 0, 1, and 2 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.6" spread="5.7"/>
                    <measurement group_id="B2" value="24.0" spread="3.3"/>
                    <measurement group_id="B3" value="26.1" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Efficacy (Defined as Prevention of Infection) of the HP Vaccine Compared to Placebo.</title>
        <description>The efficacy of the investigational vaccine to prevent infection following H.pylori challenge in healthy adults was determined in terms of percentage of subjects with positive HP infections in the vaccinated and unvaccinated groups(Placebo).
Infection rates was assessed by invasive Upper Gastrointestinal Endoscopy (UGE)tests that included HP histopathology, HP culture and rapid urease test (RUT), and non-invasive HP tests which included urea breath test (UBT) and fecal antigen test (FAT).</description>
        <time_frame>12 weeks post HP challenge</time_frame>
        <population>Per-protocol dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Group I (HP Vaccine)</title>
            <description>Subjects received three injections of H.pylori(HP) Vaccine at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) 1 month later.</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Subjects received three injections of Placebo (only aluminum hydroxide adjuvant) at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) 1 month later.</description>
          </group>
        </group_list>
        <measure>
          <title>The Efficacy (Defined as Prevention of Infection) of the HP Vaccine Compared to Placebo.</title>
          <description>The efficacy of the investigational vaccine to prevent infection following H.pylori challenge in healthy adults was determined in terms of percentage of subjects with positive HP infections in the vaccinated and unvaccinated groups(Placebo).
Infection rates was assessed by invasive Upper Gastrointestinal Endoscopy (UGE)tests that included HP histopathology, HP culture and rapid urease test (RUT), and non-invasive HP tests which included urea breath test (UBT) and fecal antigen test (FAT).</description>
          <population>Per-protocol dataset</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>UBT positive (non-invasive test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FAT positive (non-invasive test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HP culture positive (invasive test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RUT positive (invasive test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Histopathology positive (invasive test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive HP infection (Invasive+non-invasive)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Solicited Local* and Systemic Adverse Events Following Vaccination</title>
        <description>To assess the tolerability of an HP vaccine versus placebo in terms of number of subjects reporting solicited local* and systemic adverse events.</description>
        <time_frame>Day 1-7 post vaccination</time_frame>
        <population>This analysis was done on the safety dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Group I (HP Vaccine)</title>
            <description>Subjects received three injections of H.pylori(HP) Vaccine at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) 1 month later.</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Subjects received three injections of Placebo (only aluminum hydroxide adjuvant) at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) 1 month later.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local* and Systemic Adverse Events Following Vaccination</title>
          <description>To assess the tolerability of an HP vaccine versus placebo in terms of number of subjects reporting solicited local* and systemic adverse events.</description>
          <population>This analysis was done on the safety dataset</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Local*</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema*</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration*</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling*</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site warmth*</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site tenderness*</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain*</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥38C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Other#</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic antipyretic medication used#</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stayed at home due to reaction#</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Time Course of HP Infection Following HP Challenge in Vaccinated and Placebo Groups</title>
        <description>The time course of HP infection following HP challenge in subjects of the HP vaccine and placebo groups, were assessed by non-invasive HP tests.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group I (HP Vaccine)</title>
            <description>Subjects received three injections of H.pylori(HP) Vaccine at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) ≥1 month after 3rd injection.</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Subjects received three injections of Placebo (only aluminum hydroxide adjuvant) at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) ≥1 month after 3rd injection.</description>
          </group>
        </group_list>
        <measure>
          <title>The Time Course of HP Infection Following HP Challenge in Vaccinated and Placebo Groups</title>
          <description>The time course of HP infection following HP challenge in subjects of the HP vaccine and placebo groups, were assessed by non-invasive HP tests.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (UBT positive)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HP challenge (≥3 months after vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 week post challenge (UBT positive)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks post challenge (UBT positive)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 weeks post challenge (UBT positive)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks post challenge (UBT positive)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks post challenge (UBT positive)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks post challenge (UBT positive)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post eradication (UBT positive) (N=7,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (FAT positive)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 week post challenge (FAT positive)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks post challenge (FAT positive)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 weeks post challenge (FAT positive)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks post challenge (FAT positive)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks post challenge (FAT positive)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks post challenge (FAT positive)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post eradication (FAT positive) (N=7,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Geometric Mean Concentrations After HP Vaccination.</title>
        <description>The geometric mean concentration of IgG antibody responses to each of the HP vaccine antigens (VacA, CagA and NAP)after HP vaccination as compared to placebo are reported.</description>
        <time_frame>upto 1 month after 3rd vaccination</time_frame>
        <population>Per-Protocol dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Group I (HP Vaccine)</title>
            <description>Subjects received three injections of H.pylori(HP) Vaccine at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) ≥1 month after 3rd injection.</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Subjects received three injections of Placebo (only aluminum hydroxide adjuvant) at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) ≥1 month after 3rd injection.</description>
          </group>
        </group_list>
        <measure>
          <title>The Geometric Mean Concentrations After HP Vaccination.</title>
          <description>The geometric mean concentration of IgG antibody responses to each of the HP vaccine antigens (VacA, CagA and NAP)after HP vaccination as compared to placebo are reported.</description>
          <population>Per-Protocol dataset</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (CagA antigen)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.42" lower_limit="1.78" upper_limit="3.29"/>
                    <measurement group_id="O2" value="2.95" lower_limit="2.09" upper_limit="4.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after 1st vaccination (CagA antigen)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" lower_limit="1.87" upper_limit="4.48"/>
                    <measurement group_id="O2" value="2.55" lower_limit="1.55" upper_limit="4.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months after 1st vaccination (CagA antigen)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.74" lower_limit="4.83" upper_limit="12"/>
                    <measurement group_id="O2" value="2.56" lower_limit="1.5" upper_limit="4.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months after 1st vaccination (CagA antigen)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="15" upper_limit="37"/>
                    <measurement group_id="O2" value="2.54" lower_limit="1.5" upper_limit="4.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (NAP antigen)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.59" lower_limit="3.95" upper_limit="5.33"/>
                    <measurement group_id="O2" value="5.84" lower_limit="4.92" upper_limit="6.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after 1st vaccination (NAP antigen)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="25" upper_limit="50"/>
                    <measurement group_id="O2" value="5.47" lower_limit="3.68" upper_limit="8.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months after 1st vaccination (NAP antigen)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236" lower_limit="175" upper_limit="319"/>
                    <measurement group_id="O2" value="5.15" lower_limit="3.66" upper_limit="7.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months after 1st vaccination (NAP antigen)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148" lower_limit="111" upper_limit="197"/>
                    <measurement group_id="O2" value="2.54" lower_limit="1.5" upper_limit="4.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (VacA antigen)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="14" upper_limit="25"/>
                    <measurement group_id="O2" value="21" lower_limit="15" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after 1st vaccination (VacA antigen)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214" lower_limit="154" upper_limit="298"/>
                    <measurement group_id="O2" value="23" lower_limit="15" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months after 1st vaccination (VacA antigen)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2468" lower_limit="1818" upper_limit="3350"/>
                    <measurement group_id="O2" value="23" lower_limit="15" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months after 1st vaccination (VacA antigen)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="502" lower_limit="335" upper_limit="709"/>
                    <measurement group_id="O2" value="19" lower_limit="13" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations Against Vaccine Antigens After HP Challenge.</title>
        <description>The geometric mean concentration of IgG antibody responses to each of the HP vaccine antigens (VacA, CagA and NAP) after HP challenge were compared between vaccinated and placebo groups.</description>
        <time_frame>12 months</time_frame>
        <population>Per-protocol dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Group I (HP Vaccine) Infected</title>
            <description>Subjects received three injections of H.pylori(HP) Vaccine at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) ≥1 month after 3rd injection.</description>
          </group>
          <group group_id="O2">
            <title>Group I (HP Vaccine) Non-Infected</title>
            <description>Subjects received three injections of H.pylori(HP) Vaccine at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) ≥1 month after 3rd injection.</description>
          </group>
          <group group_id="O3">
            <title>Group II (Placebo) Infected</title>
            <description>Subjects received three injections of Placebo (only aluminum hydroxide adjuvant) at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) ≥1 month after 3rd injection.</description>
          </group>
          <group group_id="O4">
            <title>Group II (Placebo) Non-Infected</title>
            <description>Subjects received three injections of Placebo (only aluminum hydroxide adjuvant) at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) ≥1 month after 3rd injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations Against Vaccine Antigens After HP Challenge.</title>
          <description>The geometric mean concentration of IgG antibody responses to each of the HP vaccine antigens (VacA, CagA and NAP) after HP challenge were compared between vaccinated and placebo groups.</description>
          <population>Per-protocol dataset</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (CagA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" lower_limit="0.72" upper_limit="7.02"/>
                    <measurement group_id="O2" value="2.64" lower_limit="1.13" upper_limit="6.16"/>
                    <measurement group_id="O3" value="4.17" lower_limit="1.48" upper_limit="12"/>
                    <measurement group_id="O4" value="3.53" lower_limit="1.35" upper_limit="9.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after 1st vaccination(CagA )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24" lower_limit="0.42" upper_limit="12"/>
                    <measurement group_id="O2" value="4.54" lower_limit="1.31" upper_limit="16"/>
                    <measurement group_id="O3" value="3.84" lower_limit="0.83" upper_limit="18"/>
                    <measurement group_id="O4" value="3.06" lower_limit="0.74" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months after 1st vaccination (CagA )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.39" lower_limit="0.51" upper_limit="11"/>
                    <measurement group_id="O2" value="14" lower_limit="4.52" upper_limit="45"/>
                    <measurement group_id="O3" value="4.08" lower_limit="1" upper_limit="17"/>
                    <measurement group_id="O4" value="2.95" lower_limit="0.8" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months after 1st vaccination (CagA )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="3.29" upper_limit="48"/>
                    <measurement group_id="O2" value="93" lower_limit="34" upper_limit="250"/>
                    <measurement group_id="O3" value="3.84" lower_limit="1.13" upper_limit="13"/>
                    <measurement group_id="O4" value="2.63" lower_limit="0.85" upper_limit="8.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks post HP challenge (CagA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="4.39" upper_limit="57"/>
                    <measurement group_id="O2" value="134" lower_limit="51" upper_limit="348"/>
                    <measurement group_id="O3" value="3.92" lower_limit="1.22" upper_limit="13"/>
                    <measurement group_id="O4" value="3.59" lower_limit="1.21" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks post HP challenge (CagA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="8.89" upper_limit="102"/>
                    <measurement group_id="O2" value="261" lower_limit="105" upper_limit="648"/>
                    <measurement group_id="O3" value="4.11" lower_limit="1.35" upper_limit="13"/>
                    <measurement group_id="O4" value="3.39" lower_limit="1.21" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks post HP challenge (CagA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149" lower_limit="35" upper_limit="625"/>
                    <measurement group_id="O2" value="202" lower_limit="69" upper_limit="588"/>
                    <measurement group_id="O3" value="7.51" lower_limit="2.03" upper_limit="28"/>
                    <measurement group_id="O4" value="4.73" lower_limit="1.41" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (NAP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="2.75" upper_limit="7.04"/>
                    <measurement group_id="O2" value="4.4" lower_limit="3.1" upper_limit="6.24"/>
                    <measurement group_id="O3" value="5.46" lower_limit="3.56" upper_limit="8.38"/>
                    <measurement group_id="O4" value="11" lower_limit="7.35" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after 1st vaccination (NAP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="10" upper_limit="36"/>
                    <measurement group_id="O2" value="62" lower_limit="39" upper_limit="99"/>
                    <measurement group_id="O3" value="5.46" lower_limit="3.11" upper_limit="9.59"/>
                    <measurement group_id="O4" value="8.48" lower_limit="5.03" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 month after 1st vaccination (NAP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117" lower_limit="66" upper_limit="206"/>
                    <measurement group_id="O2" value="235" lower_limit="154" upper_limit="359"/>
                    <measurement group_id="O3" value="5.54" lower_limit="3.3" upper_limit="9.31"/>
                    <measurement group_id="O4" value="6.61" lower_limit="4.09" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 month after 1st vaccination (NAP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101" lower_limit="60" upper_limit="172"/>
                    <measurement group_id="O2" value="251" lower_limit="170" upper_limit="373"/>
                    <measurement group_id="O3" value="5.35" lower_limit="3.3" upper_limit="8.66"/>
                    <measurement group_id="O4" value="6.59" lower_limit="4.22" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks post HP challenge (NAP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125" lower_limit="75" upper_limit="209"/>
                    <measurement group_id="O2" value="275" lower_limit="187" upper_limit="404"/>
                    <measurement group_id="O3" value="5.58" lower_limit="3.49" upper_limit="8.49"/>
                    <measurement group_id="O4" value="8.3" lower_limit="5.37" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks post HP challenge (NAP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179" lower_limit="105" upper_limit="305"/>
                    <measurement group_id="O2" value="325" lower_limit="219" upper_limit="484"/>
                    <measurement group_id="O3" value="4.4" lower_limit="2.7" upper_limit="7.16"/>
                    <measurement group_id="O4" value="8.32" lower_limit="5.3" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks post HP challenge (NAP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115" lower_limit="67" upper_limit="119"/>
                    <measurement group_id="O2" value="208" lower_limit="139" upper_limit="313"/>
                    <measurement group_id="O3" value="4.4" lower_limit="2.68" upper_limit="7.24"/>
                    <measurement group_id="O4" value="8.01" lower_limit="5.05" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (VacA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="9.26" upper_limit="47"/>
                    <measurement group_id="O2" value="24" lower_limit="13" upper_limit="44"/>
                    <measurement group_id="O3" value="20" lower_limit="9.61" upper_limit="42"/>
                    <measurement group_id="O4" value="41" lower_limit="21" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after 1st vaccination (VacA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117" lower_limit="46" upper_limit="295"/>
                    <measurement group_id="O2" value="285" lower_limit="143" upper_limit="569"/>
                    <measurement group_id="O3" value="16" lower_limit="6.89" upper_limit="37"/>
                    <measurement group_id="O4" value="33" lower_limit="16" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months after 1st vaccination (VacA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1219" lower_limit="501" upper_limit="2966"/>
                    <measurement group_id="O2" value="2754" lower_limit="1419" upper_limit="5344"/>
                    <measurement group_id="O3" value="25" lower_limit="11" upper_limit="56"/>
                    <measurement group_id="O4" value="33" lower_limit="16" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months after 1st vaccination (VacA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="565" lower_limit="247" upper_limit="1292"/>
                    <measurement group_id="O2" value="979" lower_limit="529" upper_limit="1814"/>
                    <measurement group_id="O3" value="20" lower_limit="9.35" upper_limit="42"/>
                    <measurement group_id="O4" value="34" lower_limit="17" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks post HP challenge (VacA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="606" lower_limit="252" upper_limit="1453"/>
                    <measurement group_id="O2" value="912" lower_limit="475" upper_limit="1751"/>
                    <measurement group_id="O3" value="24" lower_limit="11" upper_limit="53"/>
                    <measurement group_id="O4" value="45" lower_limit="22" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks post HP challenge (VacA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2174" lower_limit="995" upper_limit="4752"/>
                    <measurement group_id="O2" value="1943" lower_limit="1085" upper_limit="3479"/>
                    <measurement group_id="O3" value="28" lower_limit="14" upper_limit="57"/>
                    <measurement group_id="O4" value="46" lower_limit="22" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks post HP challenge (VacA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3467" lower_limit="1632" upper_limit="7366"/>
                    <measurement group_id="O2" value="1469" lower_limit="838" upper_limit="2577"/>
                    <measurement group_id="O3" value="58" lower_limit="29" upper_limit="115"/>
                    <measurement group_id="O4" value="73" lower_limit="39" upper_limit="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response on Activated Regulatory T Cell Subset Following HP Vaccination and HP Challenge</title>
        <description>The response to 3 doses of HP vaccine and the oral HP challenge was assessed with respect their ability to induce differentiation and changes in the phenotype of a subset of regulatory T-cells CD4+CD25+Foxp3+ that expresses Treg Markers PD-1 and/or HLA-DR.</description>
        <time_frame>12 weeks post HP challenge</time_frame>
        <population>Per-protocol dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Group I (HP Vaccine)</title>
            <description>Subjects received three injections of H.pylori(HP) Vaccine at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) 1 month later.</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Subjects received three injections of Placebo (only aluminum hydroxide adjuvant) at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) 1 month later.</description>
          </group>
        </group_list>
        <measure>
          <title>Response on Activated Regulatory T Cell Subset Following HP Vaccination and HP Challenge</title>
          <description>The response to 3 doses of HP vaccine and the oral HP challenge was assessed with respect their ability to induce differentiation and changes in the phenotype of a subset of regulatory T-cells CD4+CD25+Foxp3+ that expresses Treg Markers PD-1 and/or HLA-DR.</description>
          <population>Per-protocol dataset</population>
          <units>percentage of T-cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening (FOXP3+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="0.33"/>
                    <measurement group_id="O2" value="1.13" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HP challenge (FOXP3+) (N=18,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.43"/>
                    <measurement group_id="O2" value="1.07" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks post challenge (FOXP3+) (N=15,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread="0.38"/>
                    <measurement group_id="O2" value="1.31" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks post challenge (FOXP3+)(N=10,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread="0.45"/>
                    <measurement group_id="O2" value="0.87" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening (HLADR TOT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" spread="8.22"/>
                    <measurement group_id="O2" value="22" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HP challenge (HLADR TOT) (N=18,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" spread="8.36"/>
                    <measurement group_id="O2" value="24" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks post challenge (HLADR TOT) (N=15,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" spread="8.36"/>
                    <measurement group_id="O2" value="21" spread="8.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks post challenge (HLADR TOT) (N=10,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" spread="7.95"/>
                    <measurement group_id="O2" value="23" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening (PD-1 TOT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="2.55"/>
                    <measurement group_id="O2" value="5.22" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HP challenge (PD-1 TOT) (N=18,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.69" spread="1.93"/>
                    <measurement group_id="O2" value="5.4" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks post challenge (PD-1 TOT) (N=15,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.12" spread="2.38"/>
                    <measurement group_id="O2" value="5.79" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks post challenge (PD-1 TOT) (N=10,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.33" spread="1.31"/>
                    <measurement group_id="O2" value="5.53" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proliferative Response Against the Pooled H. Pylori Vaccine Antigens by Stimulation Index (SI)</title>
        <description>The proliferation of H. pylori-specific Peripheral blood mononuclear cells (PBMCs) following HP antigen stimulation was assessed to measure the magnitude of the cell mediated immune response.</description>
        <time_frame>12 weeks post HP challenge</time_frame>
        <population>Per-protocol dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Group I (HP Vaccine)</title>
            <description>Subjects received three injections of H.pylori(HP) Vaccine at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) 1 month later.</description>
          </group>
          <group group_id="O2">
            <title>Group II (Placebo)</title>
            <description>Subjects received three injections of Placebo (only aluminum hydroxide adjuvant) at 0, 1, and 2 months, followed by a H.pylori challenge (oral administration of infectious HP inoculum) 1 month later.</description>
          </group>
        </group_list>
        <measure>
          <title>Proliferative Response Against the Pooled H. Pylori Vaccine Antigens by Stimulation Index (SI)</title>
          <description>The proliferation of H. pylori-specific Peripheral blood mononuclear cells (PBMCs) following HP antigen stimulation was assessed to measure the magnitude of the cell mediated immune response.</description>
          <population>Per-protocol dataset</population>
          <units>Stimulation Index (SI)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.85" spread="6.05"/>
                    <measurement group_id="O2" value="3.69" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HP challenge (N=21,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" spread="21"/>
                    <measurement group_id="O2" value="3.81" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks post challenge (N=17,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" spread="37"/>
                    <measurement group_id="O2" value="24" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks post challenge (N=13,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" spread="23"/>
                    <measurement group_id="O2" value="7.83" spread="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study period (12-14 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group I (HP Vaccine)</title>
          <description>Subjects received three injections of HP Vaccine at 0, 1, and 2 months.</description>
        </group>
        <group group_id="E2">
          <title>Group II (Placebo)</title>
          <description>Subjects received three injections of Placebo at 0, 1, and 2 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="36"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="36"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="36"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="36"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="36"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="36"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

